These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

78 related items for PubMed ID: 2891866

  • 1. Use of vasoactive agents to increase tumor perfusion and the antitumor efficacy of drug-monoclonal antibody conjugates.
    Smyth MJ, Pietersz GA, McKenzie IF.
    J Natl Cancer Inst; 1987 Dec; 79(6):1367-73. PubMed ID: 2891866
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Increased antitumor effect of immunoconjugates and tumor necrosis factor in vivo.
    Smyth MJ, Pietersz GA, McKenzie IF.
    Cancer Res; 1988 Jul 01; 48(13):3607-12. PubMed ID: 3259905
    [Abstract] [Full Text] [Related]

  • 5. Antitumor activity of idarubicin-monoclonal antibody conjugates in a disseminated thymic lymphoma model.
    Smyth MJ, Bogdanovski M, McKenzie IF, Pietersz GA.
    Cancer Res; 1991 Jan 01; 51(1):310-7. PubMed ID: 1988093
    [Abstract] [Full Text] [Related]

  • 6. Effect of tumor necrosis factor on the antitumor efficacy and toxicity of aminopterin-monoclonal antibody conjugates: parameters for optimization of therapy.
    Russell SM, Krauer KG, McKenzie IF, Pietersz GA.
    Cancer Res; 1990 Sep 15; 50(18):6028-33. PubMed ID: 2393867
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. A novel antiangiogenesis therapy using an integrin antagonist or anti-Flk-1 antibody coated 90Y-labeled nanoparticles.
    Li L, Wartchow CA, Danthi SN, Shen Z, Dechene N, Pease J, Choi HS, Doede T, Chu P, Ning S, Lee DY, Bednarski MD, Knox SJ.
    Int J Radiat Oncol Biol Phys; 2004 Mar 15; 58(4):1215-27. PubMed ID: 15001266
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Combined therapy of mice bearing a lymphokine-activated killer-resistant tumor with recombinant interleukin 2 and an antitumor monoclonal antibody capable of inducing antibody-dependent cellular cytotoxicity.
    Kawase I, Komuta K, Hara H, Inoue T, Hosoe S, Ikeda T, Shirasaka T, Yokota S, Tanio Y, Masuno T.
    Cancer Res; 1988 Mar 01; 48(5):1173-9. PubMed ID: 3257715
    [Abstract] [Full Text] [Related]

  • 13. Targeted cancer therapy: conferring specificity to cytotoxic drugs.
    Chari RV.
    Acc Chem Res; 2008 Jan 01; 41(1):98-107. PubMed ID: 17705444
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Preparation, phototoxicity and biodistribution studies of anti-carcinoembryonic antigen monoclonal antibody-phthalocyanine conjugates.
    Carcenac M, Larroque C, Langlois R, van Lier JE, Artus JC, Pèlegrin A.
    Photochem Photobiol; 1999 Dec 01; 70(6):930-6. PubMed ID: 10628305
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Experimental treatment of malignant gliomas with human monoclonal antibody-drug conjugates.
    Takahashi H, Adachi K, Yamaguchi F, Teramoto A.
    Anticancer Res; 1999 Dec 01; 19(5B):4151-5. PubMed ID: 10628367
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 4.